Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (42)

I-01Jeroen Elassaiss-Schaap

Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475

Wednesday 10:20-11:50

I-02Moran Elishmereni

Improved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects model

Wednesday 10:20-11:50

I-06Sylvain Fouliard

Cardiac safety monitoring in early oncology trials using optimal design and M&S approach

Wednesday 10:20-11:50

I-10María García-Cremades

Pharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice.

Wednesday 10:20-11:50

I-14Ekaterina Gibiansky

Population Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL)

Wednesday 10:20-11:50

I-29Stefanie Hennig

Population pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patients

Wednesday 10:20-11:50

I-32

Virtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanoma

Wednesday 10:20-11:50

I-37

Model based optimization of a novel controlled release formulation of capecitabine

Wednesday 10:20-11:50

I-41Jin Jin

Longitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell Carcinoma

Wednesday 10:20-11:50

II-19Victor Mangas-Sanjuan

Semi-mechanistic cell cycle PKPD model of chemotherapy-induced neutropenia

Wednesday 15:10-16:30

II-34Ida Neldemo

Predicting the absolute neutrophil count with frequent measurements during docetaxel-induced myelosuppression

Wednesday 15:10-16:30

II-35Yookhwan Noh

Population pharmacokinetics of HM781-36 and its metabolites in patients with advanced solid tumors

Wednesday 15:10-16:30

II-41Aziz Ouerdani

Tumor growth and angiogenesis inhibition modeling: Effects of pazopanib on preclinical and clinical tumor size data

Wednesday 15:10-16:30

II-42

Population K-PD modelling of lymph node size in lymphoma patients treated with abexinostat, a histone deacetylase inhibitor (HDACi).

Wednesday 15:10-16:30

II-43Eirini Panoilia

A population PK model for bevacizumab when combined with chemotherapy in patients with metastatic colorectal cancer stage IV

Wednesday 15:10-16:30

II-45Zinnia Parra-Guillen

Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer

Wednesday 15:10-16:30

II-48Jonás Samuel Pérez-Blanco

Population pharmacokinetic of doxorubicin and doxorubicinol in hematological patients

Wednesday 15:10-16:30

II-55Benjamin Ribba

On the use of model-based tumor size metrics to predict survival

Wednesday 15:10-16:30

III-21Dean Bottino

Operating Characteristics of Tumor Kinetic Response Assessments in Early Phase Oncology Trials

Thursday 10:05-11:30

III-24

Predicting clinical response using preclinical data: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant, prostate cancer

Thursday 10:05-11:30

III-26Claire Brillac

Population PK/PD modeling of tumor growth inhibition in tumor bearing mice: a translational strategy to predict clinical efficacy ?

Thursday 10:05-11:30

III-27René Bruno

Exposure-Response Modeling and Simulation of lucitanib Induced Dose Limiting Toxicities and Response Categories in Patients with Solid Tumors

Thursday 10:05-11:30

III-31Juan Pablo Cayun Pellizaris

Association between genetic, adverse events and pharmacokinetics in testicular cancer patients.

Thursday 10:05-11:30

III-32Pascal Chanu

Population pharmacokinetic/pharmacodynamic models to support dose selection of daratumumab in multiple myeloma patients

Thursday 10:05-11:30

III-43Pieter Colin

A model-based analysis of IPEC dosing of paclitaxel in rats.

Thursday 10:05-11:30

III-46Ana Margarita Contreras Sandoval

PK/PD modeling of new immunotherapeutic agents in cancer

Thursday 10:05-11:30

III-48Damien Cronier

A semi-mechanistic PK/PD model of vemurafenib resistance and its rescue by LY2835219, a cyclin-dependent kinase 4/6 inhibitor, in mice bearing human melanoma xenograft tumours

Thursday 10:05-11:30

III-49Chantal Csajka

Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients

Thursday 10:05-11:30

III-53

Application of Physiologically-Based Pharmacokinetic/Pharmacodynamic Modelling in Oncology

Thursday 10:05-11:30

IV-01Stefaan Rossenu

Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma

Thursday 15:15-16:40

IV-03Maria Luisa Sardu

Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments

Thursday 15:15-16:40

IV-05Emilie Schindler

PKPD-Modeling of individual lesion maximal standardized uptake value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib

Thursday 15:15-16:40

IV-10Kwang-Hee Shin

A population pharmacokinetic/pharmacodynamic approaches of a peglyated granulocyte-colony stimulating factor (G-CSF) in healthy Korean

Thursday 15:15-16:40

IV-19Mark Stroh

Meta-analysis of Published Efficacy and Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer

Thursday 15:15-16:40

IV-21Kim Stuyckens

Modelling and simulation approach to optimize the pharmacological activity during a Phase 1 study of JNJ-42756493, a selective and potent FGFR 1, 2 ,3 and 4 inhibitor.

Thursday 15:15-16:40

IV-22Siddharth Sukumaran

Development of a Mechanism-based pharmacokinetic model for MMAE conjugated ADCs

Thursday 15:15-16:40

IV-23Ahmed Suleiman

A survival modeling analysis evaluating the use of positron emission tomography with [(18)F]-fluorodeoxyglucose for predicting the prognosis in advanced non-small cell lung cancer patients first-treated with erlotinib

Thursday 15:15-16:40

IV-26Nadia Terranova

An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight

Thursday 15:15-16:40

IV-29

A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells

Thursday 15:15-16:40

IV-42Swantje Völler

Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer: Results of the EPOC-MS-001 Study

Thursday 15:15-16:40

IV-49Wenyuan Xiong

PK/PD modeling of the c-Met inhibitor MSC2156119J to establish the recommended Phase II dose

Thursday 15:15-16:40

IV-51Huixin Yu

Integrated mechanism-based pharmacokinetic model for sunitinib and its active metabolite

Thursday 15:15-16:40